Text reminders raise medication adherence in Medicare patients by 14%

Utilizing the mPulse Mobile interactive text messaging application resulted in a 14 percent increase in medication adherence in partially or nonadherent Medicare patients, according to a study published in JMIR mHealth and uHealth.

Patients with chronic conditions who do not adhere to medication schedules experience lower quality outcomes. While text messages can be used as a cost-effective method of reminding patients, research into their impact on adherence rates is lacking. In this study, researchers evaluated the feasibility and effectiveness of a personalized, interactive text messaging system to improve refill rates in partially or nonadherent Medicare patients.

Researchers used mPulse Mobile on partially adherent and nonadherent Medicare patients to compare refill rates of a text message group of 12,272 with a control group of 76,068 who did not receive text messages. All participants had experience with other forms of refill and adherence reminders like phone calls, emails and robo-calls.

Results showed a 14.1 percent increase in refill rates in the text message group when compared to refill rates of the control group.

“The results showed a strong benefit of using this text messaging solution to improve medication refill rates among Medicare patients. These findings also support using interactive text messaging as a cost-effective, convenient, and user-friendly solution for patient engagement,” concluded first author Rena Brar Prayaga, MA, JD, and colleagues. “Program outcomes and insights can be used to enhance the design of future text-based solutions to improve health outcomes and promote adherence and long-term behavior change.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.